medigraphic.com
ISSN 1561-3186 (Electronic)

2009, Number 1

<< Back Next >>

Rev Acta Médica 2009; 12 (1)

Multifactor intensive treatment of type 2 diabetes mellitus

Carrasco MB, Nuez VM

Language: Spanish
References: 27
Page:
PDF size: 173.09 Kb.


ABSTRACT

Multifactor intensive treatment of type 2 diabetes mellitus has been a radical change in medical care of these patients and its aim is to achieve an optimal control of all vascular risk factors including glycemia and also to identify the risk factors and to show the feasibility of multifactor intensive treatment in a cohort of patients with type 2 diabetes. A total of 240 patients were studied seen during two years in «Hermanos Ameijeiras» Clinical Surgical Hospital Diabetes Mellitus Consultation aged between 40 and 74 neither acute complications nor evidences of ischemic heart disease. Care was ambulatory with an integral assessment and intensive control. Risk factors included non-satisfactory glycemia control (fast glycemia › 6,1, postprandial at 2 hours. 7,8 mmol/l and/or glycosylated hemoglobin HbA1c › 7%), non-controlled high blood pressure (HBP e» 130/80 mmHg), hyperlipidemia (cholesterol > 4,7 and/or triglycerides › 1,7 mmol/L, excess weight (body mass index (BMI) e» 25 kg/m2sc). Initially, study risk factors frequency was high: non-satisfactory glycemia control (60%) and hyperlipidemia (40%). At one year there was an improvement of all risk factors control with significant differences related to onset (p ‹ 0,05) in hyperlipidemia decreasing to 9,2%, non-controlled high blood pressure to 18,3% and non-satisfactory glycemia control to 2l7,5%. Body excess weight deceased to 45,8% but without differences. We concluded that vascular risk factors were frequent in study type 2 diabetic patients, and that application of multifactor intensive treatment was feasible.


REFERENCES

  1. Carrasco B. Diabetes Mellitus Tipo 2. En: Colectivo de autores. Manual de diagnóstico y tratamiento en especialidades médicas. Hospital «Hermanos Ameijeiras», Ciudad Habana: OPS/OMS. 2002. p.176-83.

  2. Sierra ID, Mendivil CO, et al. Hacia el manejo práctico de la Diabetes Mellitus Tipo 2. Edición especial .Novo Nordisk. 2005. p.1-206.

  3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. For the multiple risk factor intervention trial research group. Diabetes, other risk factors and 12 yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993; 16: 434-44.

  4. Mogensen CE. The concept of intensified multifactorial treatment in Diabetes. Medicographia. 1995; 2:83-5.

  5. Gaede P, Vedel P, Parving HH. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet. 1999; 353:617-22 .

  6. Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O. Intervención Multifactorial y Enfermedad Cardiovascular en pacientes con diabetes Tipo2 N Engl J M. 2003; 348:383-93.

  7. Salabarría de Sanz N. Programa de educación para pacientes en tratamiento intensivo. Rev ALAD. 2003; XI(1):14-23.

  8. Guías ALAD de diagnóstico, control y tratamiento de la Diabetes Mellitus tipo 2; 2006 (URL disponible en http://www.sld.cu/sitios/diabetes/).

  9. Burlando G, Sánchez RA, Ramos FH, Mogensen CE, Zanchetti A. Consenso latinoamericano sobre diabetes mellitus e hipertensión. Journal of Hypertension. 2004; 22:2229-41.

  10. Executive Summary of the Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA. 2001;285: 486-97.

  11. Ridderstale M, Gudbjornsdottir S, Eliasson B, et al. Obesity and cardiovascular risk factors in type 2 diabetes :results from the Swedish National Diabetes Register. J Intern Med. 2006; 259:314-22

  12. Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment of diabetes and related complications . Diabetes Care. 2003; 1:S51-61.

  13. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29:1963-72.

  14. Compendio de la Guía global para la diabetes tipo 2. Diabetes Voice. 2006; 51 (Supl):19-21.

  15. Alexander CM, Landsman PB, Teustch SM, Haffner SM. Third National Health and Nutrition Examination Survey ( NHANES III) .National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52:1210-14.

  16. American Diabetes Association: Standards of medical care in diabetes: Diabetes Care 2006; 29 (Suppl 1):S4-S42.

  17. UK Prospective Diabetes Study Group. Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.

  18. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 Diabetes (UKPDS 34). Lancet. 1998; 352:854-65.

  19. UK Prospective Diabetes Study Group Tightlook pressure control and risk of macrovascular and microvascular complications in type 2 diabetes ( UKPDS 38). BMJ. 1998; 317:703-13.

  20. Dyslipidemia management en adults with Diabetes. American Diabetes Association. Diabetes Care. 2004; 27:S68-S71.

  21. Ganda OP. The role of lipid management in diabetes. Cardiol Clin. 2005; 23 (2):153-164.

  22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361:2005-16.

  23. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364:685-96

  24. Castaño G, Menéndez R, Más R, Amor A, Fernández JL, Gonzáles RL, et al. Effects of Polycosanol and Lovastatin on lipid profile and lipid peroxidation in patients with Dyslipidemia associated with Type 2 Diabetes Mellitus. Int J Clin Pharm Res. 2002; XXII (3/4):89-100.

  25. Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004; 27:2067-73.

  26. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. Am Coll Nutr 2003; 22:331- 39.

  27. Carrasco B, Benavides R, Barranco E. Repercusión del control integral de factores de riesgo modificables sobre la progresión de la nefropatía en diabéticos tipo 2. Trabajo de terminación de Residencia. Hospital Clínico Quirúrgico «Hermanos Ameijeiras». Ciudad de La Habana. 2001.




2020     |     www.medigraphic.com